Intelligence / Healthtech / New Clinical Trials / FUSMobile Inc.
FUSMobile Inc.
9 Nov 2026: Trial registered · Study Designed to Assess the Efficacy and Safety of the Neurolyser XR After Marketing Approval. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 9 Nov 2026
- Title
- Study Designed to Assess the Efficacy and Safety of the Neurolyser XR After Marketing Approval
- Conditions
- Lumbar Zygapophyseal Pain, Low Back Pain, Facet Joint Pain; Low Back Pain
- Study Type
- Observational
- Status
- Not Yet Recruiting
- Countries
- Spain
- Country
- Spain
- Reference
- NCT07926581
- Location
- Spain
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at FUSMobile Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for FUSMobile Inc. in our registers.
More from Spain
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.